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Background: The value of microRNAs (miRNAs) as novel targets for cancer therapy is now widely recognized.
However, no information is currently available on the expression/functional role of miRNAs in diffuse malignant
peritoneal mesothelioma (DMPM), a rapidly lethal disease, poorly responsive to conventional treatments, for which the
development of new therapeutic strategies is urgently needed. Here, we evaluated the expression and biological
effects of miR-34a—one of the most widely deregulated miRNAs in cancer and for which a lipid-formulated mimic is
already clinically available—in a large cohort of DMPM clinical samples and a unique collection of in house-developed
preclinical models, with the aim to assess the potential of a miR-34a-based approach for disease treatment.
Methods: miR-34a expression was determined by qRT-PCR in 45 DMPM and 7 normal peritoneum specimens as well
as in 5 DMPM cell lines. Following transfection with miR-34a mimic, the effects on DMPM cell phenotype, in terms of
proliferative potential, apoptotic rate, invasion ability, and cell cycle distribution, were assessed. In addition, three
subcutaneous and orthotopic DMPM xenograft models were used to examine the effect of miR-34a on tumorigenicity.
The expression of miRNA targets and the activation status of relevant pathways were investigated by western blot.
Results: miR-34a was found to be down-regulated in DMPM clinical specimens and cell lines compared to normal
peritoneal samples. miR-34a reconstitution in DMPM cells significantly inhibited proliferation and tumorigenicity,
induced an apoptotic response, and declined invasion ability, mainly through the down-regulation of c-MET and AXL
and the interference with the activation of downstream signaling. Interestingly, a persistent activation of ERK1/2 and
AKT in miR-34a-reconstituted cells was found to counteract the antiproliferative and proapoptotic effects of miRNA, yet
not affecting its anti-invasive activity.
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Conclusions: Our preclinical data showing impressive inhibitory effects induced by miR-34a on DMPM cell proliferation,
invasion, and growth in immunodeficient mice strongly suggest the potential clinical utility of a miR-34a-replacement
therapy for the treatment of such a still incurable disease. On the other hand, we provide the first evidence of a potential
cytoprotective/resistance mechanism that may arise towards miRNA-based therapies through the persistent activation of
RTK downstream signaling.
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Diffuse malignant peritoneal mesothelioma (DMPM) is
an uncommon though locally aggressive tumor that
develops from mesothelial cells lining the peritoneal
cavity [1]. DMPM prognosis is dismal and standard ther-
apy, including palliative surgery, systemic/intraperitoneal
chemotherapy, and abdominal irradiation, showed to be
ineffective, with a median survival of about 1 year [1].
Currently, the most effective treatment is a loco-regional
approach combining aggressive cytoreductive surgery
(CRS) with hyperthermic intraperitoneal chemotherapy
(HIPEC), which significantly extended survival in selected
series of patients [1]. However, for recurrent patients and
for those who are not eligible to CRS+HIPEC, the progno-
sis remains severe due to the lack of alternative treatment
options [2]. Considering the rarity of the disease and the
unavailability of experimental models, the biology of
DMPM is still largely unknown. It is anticipated that
advances in the knowledge of the mechanisms responsible
for the biological aggressiveness and the relative chemore-
sistance of DMPM will allow the identification of relevant
targets for the development of novel therapeutic strategies.
MicroRNAs (miRNAs) are single-stranded endogenous
evolutionary conserved, non-coding RNA molecules acting
as post-transcriptional regulators of gene expression [3].
Deregulated miRNA expression and/or function have been
observed in a variety of human solid and hematological
tumors and have been causatively linked to the pathogen-
esis of cancer [4]. Depending on their expression levels,
cellular context, and target functions, miRNAs can act as
oncogenes or tumor suppressors [4] and may represent
novel targets or tools for cancer therapy [5].
MiR-34a is one of the most widely studied miRNAs in
cancer. Its expression has been found to be decreased in a
variety of human tumors [5] due to DNA copy number
loss or epigenetic silencing through aberrant CpG methy-
lation [6, 7]. Results of studies where the expression of
miR-34a was manipulated in human tumor experimental
models clearly showed that the miRNA acts as a tumor
suppressor by regulating highly relevant processes such as
proliferation, cell cycle, apoptosis, invasion, and metastasis
[8]. Reinforced expression of miR-34a has been found to
positively modulate drug response in cancer cells [8]. In
addition, a liposomal nanoparticle-formulated syntheticmiR-34 (MRX34) recently entered a phase I clinical study
for patients with different tumor types [9].
No information concerning the expression and/or the
functional role of miRNAs in DMPM is currently available
in the literature. Based on the knowledge that several recep-
tor tyrosine kinases (RTKs) are validated targets of miR-34a
[8] and our previous results indicating that activation of
downstream RTK signaling, in terms of phosphorylation/
overexpression of extracellular signal regulated kinase ½
(ERK1/2), AKT, and mTOR, is present in a considerable
fraction of DMPM clinical specimens [10], we proposed to
investigate the possible relevance of miR-34a in the disease,
with the final aim to develop novel therapeutic strategies.
Here, we report that miR-34a is down-regulated in DMPM
clinical specimens and demonstrate that miR-34a replace-
ment in a unique collection of in-house-developed human
DMPM experimental models [11–13] inhibits cell prolifera-
tion and invasion and impairs tumor growth formation in
SCID mice, mainly as a consequence of c-METand AXL in-
hibition. These findings identified miR-34a-AXL and -c-
MET axes as promising therapeutic targets for DMPM.
Moreover, we provide evidence of persistent activation of
ERK1/2 and AKTas a possible cytoprotective mechanism to
RTK inhibition by miR-34a.
Methods
Clinical samples
Forty-five DMPM specimens classified as epitheliod (40),
sarcomatoid (1), and biphasic (4) from patients treated with
CRS+HIPEC at the Fondazione IRCCS Istituto Nazionale
dei Tumori, Milan (INT) from October 1997 to February
2013, and 7 normal peritoneum specimens from patients
who underwent surgery for non-oncologic disease were
available for miR-34a expression analysis.
This study was approved by the Institutional Review
Board and Ethical Committee and each patient provided
written informed consent to donate to INT the leftover
tissue after diagnostic and clinical procedures.
Cell lines and culture conditions
The human mycoplasma-free DMPM cell lines MesoII,
STO, MP115, MP4, and MP8 were established in our
laboratory [11–13]. All cells were cultured in DMEM F-12
medium (Lonza, Milano s.r.l., Treviglio, Italy) supplemented
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incubator. Cell lines were authenticated by single-tandem
repeat analysis by the AmpFISTR Identifiler PCR amplifica-
tion kit (Applied Biosystems, Foster City, CA, USA).
Cell transfection
Mimic pre-miR-34a precursor (miR-34a) and mimic
negative control (Neg) were purchased as Pre-miR™
miRNA precursor molecules (Thermo Fisher Scientific,
Monza, Italy). Knockdown of AXL and c-MET was per-
formed using specific siRNAs (siAXL and siMET; ON-
TARGET plus SMART pool) and, as a control, a siRNA
with a nonsense/scrambled sequence (siNeg, ON-
TARGET plus non-Targeting Pool) (Dharmacon, CO,
USA) was used. Cells were transfected for 24 h with
20 pM miR-34a or Neg, or 100 nM siAXL, siMET, or
siNeg, using Lipofectamine® RNAiMAX Transfection
Reagent (Thermo Fisher Scientific) with Opti-MEM I
(Gibco, NY, USA) according to the manufacturer’s
instructions.
RNA extraction, cDNA synthesis, and qRT-PCR
Quantification of miR-34a expression levels was assessed
by qRT-PCR. Total RNA was isolated using the miRNeasy
Mini Kit (QIAGEN, Hilden, Germany) and 1 μg of RNA
was reverse transcribed by miScript II RT Kit (QIAGEN).
Mature miRNA expression was assayed by miScript Primer
Assays specific for miR-34a (MS00003318) and normalized
on SNORD48 (MS00007511) (QIAGEN). Quantitative RT-
PCR was conducted using miScript SYBR Green PCR Kit
(QIAGEN). The reaction was carried out in a 96-well PCR
plate at 95 °C for 15 min followed by 40 cycles of 94 °C for
15 s, 55 °C for 30 s, and 70 °C for 30 s and a dissociation
step to distinguish specific from non-specific amplification
products. Each sample was analyzed in triplicate.
Amplifications were run on the 7900HT Fast Real-
Time PCR System (Applied Biosystem). Data were ana-
lyzed by SDS 2.2.2 software (Applied Biosystems) and re-
ported as -ΔCt, that is the difference between the Ct of
the target gene and the Ct of the housekeeping gene
(where Ct is the threshold cycle), or as relative quantity
(RQ) or -ΔΔCt with respect to a calibrator sample (i.e.,
negative control transfected cells) according to the 2
−ΔΔCt method.
Cell growth assay
To assess the effect of miR-34a restoration on cell prolif-
eration, DMPM cells were transfected with Neg or miR-
34a as described above. At different intervals from trans-
fection, cells were trypsinized and counted in a particle
counter (Beckman Coulter, Cassina de’ Pecchi, Italy). Re-
sults were expressed as percent variation in the number
of miR-34a-transfected cells compared with Neg-
transfected cells.Immunoblotting analyses
Cell lysates were fractionated by SDS-PAGE, transferred
to nitrocellulose membranes, and probed with specific
antibodies, as described in [14]. Cells were lysed and
western blot was performed using the following primary
antibodies: anti-c-MET, −CDK6, −uPA, −pospho-FAK
(Tyr 576/577) (Santa Cruz Biotechnology, CA, USA);
anti-AXL, −phospho-AKT (Ser473), −phospho-p44/42
MAPK (ERK1/2) (Thr202/Tyr204), −p44/42 MAPK
(ERK1/2), −FAK, −cleaved CPP32 (Cell signaling, Bev-
erly, USA); anti-AKT (BD Biosciences, San Jose, CA,
USA); and anti-actin and -vinculin (Sigma Chemical
Company, St. Louis, MO, USA).
Secondary antibodies used were conjugated to horse-
radish peroxidase (GE Healthcare, Little Chalfont, UK).
Immunostained bands were detected by chemolumines-
cence method (ECL, GE Healthcare). In many experi-
ments, membranes were stripped and reblotted with a
second antibody. Moreover, membranes were cropped to
allow simultaneous incubation of different primary anti-
bodies on the same samples. For the preparation of fig-
ures, we cropped the original western blot to generate
the appropriate figure panels with the relevant lanes.
This cropped image was then subjected to uniform
image enhancement of contrast and brightness. Molecu-
lar weights were determined using the Precision Plus
Protein™ Standard (Bio-Rad, Segrate, Italy), which yields
a colorimetric image only and has been removed from
the chemoluminescent blot image.Drugs
The AKT-1/2 inhibitor trifluoroacetate salt hydrate
(A6730, Sigma Chemical Company) and the MEK inhibi-
tor CI-1040 (PD184352, Selleck Chemicals, Houston,
TX, USA) were dissolved and diluted in DMSO. Final
concentration of DMSO in cell cultures never exceeded
0.5%. The antiproliferative activity was evaluated by cell
counting at different times after exposure of miR34a-
reconstituted MesoII cells to drug concentrations able to
inhibit cell proliferation by 20% (IC20).Apoptosis detection and cell cycle analysis
At different time points after transfection with miRNAs
mimic or siRNAs, floating and adherent cells were har-
vested and processed for apoptosis evaluation by
TUNEL assay according to manufacturer’s instructions
(Roche, Mannheim, Germany) and for cell cycle [15].
For cell cycle, cells were fixed in 70% ethanol 96 h after
transfection, stained in phosphate-buffered saline (PBS)
containing 10 μg/ml propidium iodide (PI; Sigma Chem-
ical Company), and RNase A (66 U/ml; Sigma Chemical
Company) for 18 h and analyzed by FACScan flow cyt-
ometer (Becton Dickinson, Mountain View, CA, USA).
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Cells were transfected with miR-34a or Neg for 24 h. Sam-
ples were washed in PBS 72 h after transfection and proc-
essed for senescence-associated β-galactosidase (SA-β-Gal)
staining. Cells were fixed for 5 min (room temperature) in
2% formaldehyde/0.2% glutaraldehyde, washed and incu-
bated overnight at 37 °C (no CO2) with fresh solution as
previously described [15]. At least 300 cells were examined,
and the results were expressed as percentage of SA-β-Gal
positive cells over the whole population.
Transwell invasion assay
Invasion assay was performed 72 h after transfection using
a 24-well Boyden chamber with 8-mm pore size filter in
the inset chambers (Costar, Corning Inc., NY, USA). The
Transwell membranes were previously coated with
3.47 μg Matrigel/well (BD Biosciences) and dried for
30 min. Cells were suspended in 300 μL serum-free
medium and seeded into the insert chambers. After 24 h
of incubation at 37 °C in 5% CO2, cells that migrated into
the bottom chamber containing 1 ml of serum-free
medium were fixed in 95% ethanol, stained with a solution
of 0.4% sulforhodamine B in 0.1% acetic acid, counted
under an inverted microscope, and then photographed.
Antibody arrays and ELISA
Cells were seeded at 2 × 104 cells/dish in complete medium
and transfected with Neg or miR-34a for 24 h before serum
starvation for 72 h. Conditioned media were then harvested
and clarified by centrifugation at 13,000 rpm for 15 min.
Cells were trypsinized, counted, and lysed for assaying pro-
tein content. Supernatant aliquots were used to assess
angiogenesis-related protein content by Antibody Arrays
(R&D System, SPACE Import Export, Milan, Italy) accord-
ing to manufacturer’s instructions. The ELISA kit for
Maspin (human Maspin “Super X” ELISA Kit, Antigenix
America, Huntington Station, NY, USA) was used according
to the manufacturer’s instructions for quantitative analysis.
In vivo experiments
All experimental protocols were approved by the Ethics
Committee for Animal Experimentation of INT. Experi-
ments were performed using 8-week-old female SCID
mice (Charles River, Calco, Italy). Each group contained
five to six mice. Cells were transfected with miR-34a or
Neg for 24 h, as described above, and then inoculated
subcutaneously or intraperitoneally after the analysis of
the transfection efficiency by qRT-PCR.
Subcutaneous tumor models
STO, MesoII, and MP8 cells were injected subcutaneously
into the right flank (1–1.2 × 107 cells/mouse). Inoculated
animals were inspected daily to establish the time of tumor
onset. Tumor growth was measured every 2 to 3 days usinga Vernier caliper (Table 1). The subcutaneous tumor
volume was calculated as follows: TV (mm3) = d2 ×D/2
where d and D are the shortest and the longest diameter,
respectively. Volume inhibition percentage (TVI%) in
tumors derived from miR-34a- over Neg-transfected cells
was calculated as follows: TVI% = 100− (mean miR-34a
TV/mean Neg TV× 100).
Proteins were obtained as described previously [16]
from frozen s.c. tumors derived from two additional mice
sacrified at different time points. Briefly, samples were
pulverized by Mikro-Dismembrator II (B. Brown Biotech
International, Melsungen, Germany) and suspended in
lysis buffer supplemented with protease and phosphatase
inhibitors. Proteins were processed as described [16].
Intraperitoneal (orthotopic) tumor models
STO and MP8 cells were injected into the peritoneal
cavity (107 and 2.5 × 107 cells/mouse, respectively). Ani-
mals were monitored and weighed daily and sacrificed at
different times from cell injection (Table 2). A careful
necropsy was performed to evaluate the take rate and
spread of mesothelioma cells in the abdominal cavity.
Solid masses were gently detached from organs and ab-
dominal walls, removed, and weighed for calculating the
percentage of tumor weight inhibition (TWI %) in mice
inoculated with miR-34a- over Neg-transfected cells.
Statistical analyses
If not otherwise specified, in vitro data are presented as
mean values ± SD from at least three independent experi-
ments. Statistical analysis of the data was performed by
two-tailed Student’s t test. For in vivo data, two-tailed
Student’s t and Fisher’s exact test were used to compare
tumor volumes/weights and tumor takes, respectively.
Patient survival analysis was performed using Cox propor-
tional regression model [17]. p values <0.05 were consid-
ered statistically significant.
Results
miR-34a is down-regulated in DMPM clinical samples and
cell lines
We first evaluated miR-34a expression by qRT-PCR in 45
DMPM and 7 normal peritoneum specimens as well as in
5 unique cell lines established in our laboratory from clin-
ical samples of epithelioid (STO, MP4, MesoII, MP8) and
biphasic (MP115) DMPM. Results indicated that miR-34a
abundance is significantly reduced in DMPM compared to
normal tissues (Fig. 1). Consistently, miR-34a expression
was found down-regulated in all DMPM cell lines, thus
indicating an oncosuppressive function of the miRNA also
in this disease.
No significant difference in miR-34a expression was
observed as a function of demographic and clinico-
pathologic characteristics, including gender, histologic
Table 1 Effect of miR-34a reconstitution on DMPM cell tumorigenicity following s.c. injection in SCID mice
Model miRNA Engrafted tumors/
total micea
Tumor onsetb TV (mm3) TVI %c (day) p valued
STO Neg 6/6 1 440 ± 94
miR-34a 6/6 1 188 ± 39 57 (10) 0.0003
MesoII Neg 5/5 7 201 ± 93
miR-34a 5/5 12 9 ± 12 96 (12) 0.0035
MP8 Neg 5/5 18 72 ± 35
miR-34a 5/5 25 1 ± 2 98 (21) 0.0041
aNumber of mice presenting s.c. tumors out of number of cell-injected mice
bMedian day of tumor appearance
cTumor volume inhibition % in miRNA34a- over Neg-transfected cell-injected mice
dBy Student’s t test over Neg-transfected cell-injected mice
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shown). In addition, at 5 years of follow-up, miR-34a
expression did not significantly affect the probability of
disease-free survival of DMPM patients (high expressing
versus low expressing—categorized on the basis of the
median miR-34a expression value—36 versus 20%; hazard
ratio, 1.85; 95% confidence interval, 0.86–4.01; p = 0.11).
Overall, such findings suggest a role for miR-34a as a
possible therapeutic target rather than a prognostic/pre-
dictive biomarker in DMPM.
miR-34a reconstitution variably affects DMPM cell growth
and apoptosis
To functionally assess the possible role of miR-34a as a
novel therapeutic target in DMPM, we transiently trans-
fected cells with miR-34a synthetic mimic and miRNA
negative control. As assessed by qRT-PCR, marked in-
crease in miRNA abundance was consistently observed in
all cell lines at 24 h from transfection (Additional file 1:
Figure S1) and was still maintained, although to a lesser
extent, at 168 h (Additional file 1: Figure S1 and data not
shown). miR-34a reconstitution significantly inhibited the
proliferation of four out of five DMPM cell lines in a
time-dependent manner, though with a different kinetics
(Fig. 2a). Specifically, a more rapid cell growth decline was
observed in STO and MP4 cells (~80% inhibition at 96 and
168 h, respectively), whereas, in MesoII and MP8 cells, the
same level of inhibition was recorded at later time points
(192 and 216 h, respectively) (Fig. 2a). Conversely, ectopicTable 2 Effect of miR-34a reconstitution on DMPM cell tumorigenic
Model miRNA Day of sacrifice Engrafted tumors/total micea p va
STO Neg 14 5/5
miR-34a 1/5 0.047
MP8 Neg 31 5/5
miR-34a 5/5
aNumber of mice presenting i.p. tumors out of number of cell-injected mice
bBy Fisher’s exact test over Neg cell-injected mice
cTumor weight inhibition % in miRNA34a- over Neg-transfected cell-injected mice
dBy Student’s t test over Neg-transfected cell-injected miceexpression of miR-34a only induced a weak inhibition
(~30%) of MP115 cell growth, which was almost constant
until the end of the experiment (Fig. 2a).
The variable antiproliferative effects consequent to miR-
34a reconstitution in the different DMPM cell lines was
paralleled by a different kinetics of apoptosis induction, as
detected by TUNEL assay (Fig. 2b). Specifically, a signifi-
cant enhancement in the percentage of apoptotic cells was
already appreciable at 96 h upon transfection of STO and
MP4 cells, whereas the apoptotic response was induced at
a later time point (168 h) in MP8 and MesoII cells
(Fig. 2b). No induction of apoptotic cell death was
observed in MP115 cells until 216 h after miR-34a recon-
stitution (Fig. 2b).
To investigate whether validated targets of miR-34a
were modulated by its synthetic mimic in DMPM cells,
we assessed protein expression levels of c-MET, AXL,
and CDK6 considering their established role in the
control of cell proliferation and apoptosis in different
tumor types [8, 19–21]. A marked down-modulation of
the three proteins was consistently observed in all
DMPM cell lines (Fig. 2c), regardless of the effects
induced by miR-34a reconstitution on cell growth and
apoptosis.
ERK1/2 and AKT activation as a possible cytoprotective
mechanism following miR-34a reconstitution
Based on the evidence that the activation of downstream
RTK signaling pathways, including PI3K/AKT and RAF/ity following i.p. injection in SCID mice
lueb Tumor weight (mg) Average value TVI (% Neg)c p valued
10, 80, 80, 100, 110 76
6 0, 0, 0, 0, 10 2 97 0.0029
130, 310,250, 210,150 210
80, 90, 70, 120, 80 88 58 0.0071
Fig. 1 Expression levels of miR-34a. qRT-PCR analysis of miR-34a expression using total RNA from fresh normal peritoneum tissues (n = 7), DMPM
clinical samples (n = 45), and DMPM cell lines (STO, MP4, MesoII, MP8, MP115). Data were presented as 2−ΔCt (miR-34a-SNORD48) values (**p < 0.01;
***p < 0.001; ****p < 0.0001 by Student’s t test)
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nant pleural [22] and peritoneal [10] mesothelioma, we
evaluated the effect of miR-34a reconstitution on the phos-
phorylation status of AKT and ERK1/2 in DMPM cell lines.
A reduced abundance of phospho-ERK1/2 and phospho-
AKT was appreciable in STO cells at 72 and 96 h after
transfection with miR-34a mimic (Fig. 2c). A reduced ex-
pression of phospho-ERK1/2 was also observed in miR-
34a-reconstituted MP4 and MP8 cells at the latter time
point (Fig. 2c). Consistent with the delayed antiproliferative
and proapoptotic response following miR-34a reconstitu-
tion, a decline in the expression levels of phospho-ERK1/2
and phospho-AKT was observed in MesoII cells at only
168 h (Fig. 2c, d), whereas no decrease in the abundance of
the two phopho-proteins was found in the less sensitive
MP115 cell line at either time point (Fig. 2c, d).
To assess whether activation of AKT or MAPK/ERK1/2
signaling pathways, which is a well-known mechanism of
resistance to RTK inhibitors [23–26], could also represent
a cytoprotective mechanism to the oncosuppessive effects
of miR-34a, we exposed miRNA-reconstituted MesoII
cells to subtoxic concentrations of small-molecule AKT
(A6730) and MEK1 (CI-1040) inhibitors (Fig. 3a). Interest-
ingly, inactivating ERK1/2 or impeding the reactivation of
AKT only slightly affected MesoII response to miR-34a,
whereas the concomitant blockade of the two pathways,
made the sensitivity profile of MesoII cells superimposable
on that of the inherently sensitive STO cell line (Fig. 3b).
Such a growth inhibitory effect was paralleled by an earlier
onset of apoptosis, as detected by caspase-3 cleavage
(CPP32) at 96 h (Fig. 3a).
To better characterize the cytostatic—rather than cyto-
toxic—effect observed in MP115 cells following miR-34a
reconstitution, we assessed cell cycle distribution by flow
cytometry. A cell accumulation in the G1-phase, which was
paralleled by an enhanced fraction of senescence-associated
β-galactosidase-positive cells, was observed (Fig. 4a, b).
Such a senescence-like phenotype, which was not appre-
ciable in the other DMPM cell models (Fig. 4b and datanot shown), could be related to the marked phospho-AKT
accumulation observed in miR-34a-reconstituted MP115
cells, according to previous evidence indicating that consti-
tutively active AKT induces senescence in human endothe-
lial cells and human fibroblasts [27, 28].
miR-34a oncosuppressive activities mainly rely on c-MET
and AXL inhibition
To corroborate the hypothesis that miR-34a oncosuppres-
sive functions mainly rely on the down-regulation of c-
MET and AXL, we performed siRNA-based phenocopy
experiments (Additional file 2: Figure S2). When trans-
fected into STO cells, which do not inherently express
AXL, siMET was able to recapitulate the effects induced
by miR-34a reconstitution, in terms of cell growth inhib-
ition (Fig. 5a), apoptosis induction (Fig. 5b), impairment
of invasive capability (Fig. 5c), and inactivation of both
ERK1/2 and AKT pathways (Additional file 2: Figure S2).
In MesoII cells, siMET did not appreciably affect cell
proliferation, apoptosis, or invasion (Fig. 5a–c). Con-
versely, siAXL reduced MesoII proliferation, although a
cell growth inhibition comparable to that induced by miR-
34a reconstitution was only observed following combined
silencing of c-MET and AXL (Fig. 5a). Interestingly, siAXL
alone phenocopied the effects of miR-34a, in terms of
apoptosis and invasion (Fig. 5b, c), suggesting a main role
of this RTK in mediating the oncosuppressive effects of
miR-34a in MesoII cells. Moreover, AXL silencing did not
inhibit AKT and ERK1/2 signaling pathways similarly to
miR-34a reconstitution (Additional file 2: Figure S2).
The decreased EGFR abundance observed in miR-34a-
reconstituted STO and MesoII cells (Additional file 3:
Figure S3a), together with preliminary evidence indicating
that the RTK is expressed/activated in DMPM clinical
specimens [10], prompted us to investigate a possible role
for EGFR down-regulation in sustaining the miR-34a-
induced cell phenotype. However, siEGFR failed to affect
cell growth and invasion capability in both cell lines
(Additional file 3: Figure S3b).
Fig. 2 Effects of miR-34a reconstitution on DMPM cell proliferation, apoptosis, and RTK signaling pathways. a Antiproliferative effects of miR-34a. DMPM cell
growth was assessed by cell counting. Data are expressed as percentage of the proliferation of miR-34a- versus miRNA negative control (Neg)-transfected
cells. Means ± SD values of three independent experiments are reported. b Proapoptotic effects of miR-34a. Quantitative analysis of TUNEL-positive DMPM
cells transfected with transfection reagent (Ctrl), Neg, or miR-34a was carried out by flow cytometry at different time points after transfection. Mean ± SD
values of three independent experiments are reported (**p< 0.01; ***p< 0.001 by Student’s t test). c, d Effects of miR-34a on validated miRNA targets and
RTK downstream signaling cascades as assessed by western blot analysis at 72, 96 (c) and 168 (d) h after cell transfection with Ctrl, Neg, or miR-34a. Actin
was used to confirm equal protein loading. A representative experiment of three was reported. Cropped images of selected proteins are shown
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impairs the secretion of angiogenesis-related factors
Enforced expression of miR-34a significantly inhibited inva-
sion of all DMPM cell models, as detected in a matrigel-
based assay at 72 h after transfection (Fig. 6a), likely as a
consequence of c-MET or AXL down-regulation. c-MET
and AXL signaling pathways are indeed known to affect cell
motility and invasion primarily through the activation of
mitogen-activated protein kinase (MAPK) [29–32]. How-
ever, since a decreased invasive potential was observed also
in MesoII and MP115 cells in spite of MAPK iperactivation
(Fig. 2c), the status of focal adhesion kinase (FAK), knownto mediate cell migration and anchorage-independent
growth downstream of RTKs [29–33], was assessed. Inter-
estingly, miR-34a ectopic expression consistently reduced
FAK posphorylation at Y576/577 in STO, MesoII, and
MP115 cell models, suggesting that miR-34a-induced in-
hibition of cell invasion can occur regardless of MAPK and
AKTactivation (Fig. 6b).
Since AXL and c-MET inhibition by drugs and mono-
clonal antibodies was shown to induce antiangiogenic ef-
fects in tumors [34, 35], we investigated whether miR-34a
reconstitution was able to affect the production/release of
angiogenesis-related proteins by DMPM cells. We found
Fig. 3 Inhibition of AKT and ERK1/2 signaling pathways increases the antiproliferative and proapoptotic effects of miR-34a. MesoII cells were trans-
fected with Ctrl, Neg, or miR-34a for 24 h and successively exposed to vehicle (DMSO, unt) or low concentrations (corresponding to IC20 values) of
A6730 (AKT inhibitor, 5 μM) and/or CI-1040 (MEK inhibitor, 3 μM). a Expression and phosphorylation status of AKT and ERK1/2 and amount of cleaved
CPP32 at 72 h after drug treatment were assessed by western blot. Actin was used to confirm equal protein loading. A representative experiment of
three was reported. The panel shows cropped blots. b The effects of AKT and MEK inhibitors on the growth of miR-34a-transfected cells were assessed
by cell counting. Data are expressed as percentage of the proliferation of miR-34a- versus Neg-transfected cells. The cell growth inhibition curve of
STO cells after enforced expression of miR-34a was reported for comparison. Means ± SD values of three independent experiments are shown
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secretion of angiogenesis-related molecules (Fig. 7).
Indeed, antibody array results obtained in conditioned
medium of miR-34a-reconstituted cells (at 72 h following
transfection) showed a reduced secretion of the
urokinase-type plasminogen activator (uPA), which plays
a major role in promoting angiogenesis [36], together with
and increased release of maspin, a member of the serine
protease inhibitor (serpin) superfamily, which exerts anti-
angiogenic effects through the inhibition of both the
growth and migration of endothelial cells [37, 38] (Fig. 7a).
Western blot and ELISA experiments carried out on the
same conditioned media confirmed a reduced expressionof uPA precursor (Fig. 7b) and an increased abundance of
maspin (Fig. 7c).
miR-34a reconstitution inhibits tumor formation in SCID mice
To investigate whether miR-34a reconstitution affected
DMPM formation in vivo, we subcutaneously (STO,
MesoII, MP8) and intraperitoneally (STO, MP8) inoculated
miR-34a mimic- or miRNA negative control-transfected
cells into SCID mice. Results indicate that miR-34a consist-
ently impaired the growth of all s.c. xenograft models, with
maximum tumor volume inhibitions ranging from 57 to
98% (Fig. 8 and Table 1). In addition, an appreciably delayed
tumor onset was observed for MesoII and MP8 cell models
Fig. 4 miR-34a induces a senescence-like phenotype in MP115 cells. a At 96 h following transfection of STO and MP115 cells with Ctrl, Neg, or
miR-34a, nuclei were stained with propidium iodide and analyzed for DNA content by FACScan. Data (mean ± SD of three independent experiments)
represent the percentage of cells in the different cell cycle phases. b Left panel: representative micrographs of SA-β-gal staining of STO and MP115 cells
transfected with Neg or miR-34a. Blue precipitation in the cytoplasm was observed in the senescent cells. Original magnification, × 40. One representative
experiment of three was shown. Right panel: histogram bars represent the mean percentage of SA-β-gal positive cells ± SD of at least three independent
experiments (**p< 0.01 by Student’s t test)
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from additional mice sacrificed at different time points after
DMPM cell inoculum indicated a decreased expression of
c-MET in all xenograft models and AXL in MesoII and
MP8 models (Fig. 8b), in accordance with in vitro results.
As regards i.p. xenograft models, at necropsy, all control
mice showed a large tumor mass at the site of cell injection
mainly invading the peritoneum wall and widespread small
nodules in the peritoneum and attached to the diaphragm,
liver, and bowel. Conversely, only one mouse out of the five
mice receiving miR-34a-reconstituted STO cells developed
small tumor nodules in the abdominal cavity (Table 2).
miR-34a ectopic expression did not influence the take of
MP8 cells but markedly reduced their growth, as indicated
by a significantly reduced tumor weight (Table 2).
Discussion
No information is currently available on the expression and
functional role of miRNAs in DMPM. Here, we demon-
strated that miR-34a is down-regulated in a large series of
DMPM clinical samples and in a unique panel of cell lines,
established from DMPM patients in our laboratories, com-
pared to normal peritoneum specimens. We also illustrated
that miR-34a exerts oncosuppressive functions in our
tumor models, consistent to what previously observed in a
variety of human tumor types [5, 39–41]. Indeed, miR-34a
reconstitution impaired proliferation and induced an
apoptotic response in DMPM cell lines, although at a vari-
able extent and with different kinetics, mainly through the
down-regulation of c-MET and AXL and the interference
with the activation of downstream signaling. Interestingly,
results also indicated that a transient or persistent activation
of ERK1/2 and AKT can delay or prevent the cytotoxic and
proapoptotic effects of miR-34a reconstitution, as observed
in MesoII and MP115 cells, respectively. Noteworthy,
DMPM cell feedback to AXL and c-MET down-regulationinduced by miR-34a reconstitution is to directly activate
ERK1/2 and AKT survival signaling cascades rather than
up-regulate the expression levels of the receptors, thus en-
suring a more prompt counter-response. Such findings pro-
vide the first evidence that tumor cells can exploit a well-
known mechanism of resistance to RTK inhibitors—i.e., the
activation of RTK downstream signaling [23–26]—to coun-
teract the antiproliferative/proapoptotic effects of miR-34a.
However, such a mechanism was not found to protect
DMPM cells from the anti-invasive effect of the miRNA.
Noteworthy, the cytoprotective mechanism based on
ERK1/2 andAKTactivationwasmainly evident in theDMPM
cell lineMP115, derived from a biphasic subtype tumor. Such
subtype is known to be more aggressive and associated with a
reduced patient survival compared to the epithelioid [42],
although differences in specific relevant biological properties
between the two DMPM subtypes are currently unknown. In
addition, the delayed pro-apoptotic and cytotoxic effects
observed inMesoII cells followingmiR-34a reconstitution are
consistent with the finding that, unlike other epithelioid cell
lines, they carry amutant p53 [11].
A novel mechanism of miR-34a-dependent AKT inhibition
has been recently proposed by Wang et al. [43]. In this study,
miR-34a is reported to inhibit Bmi-1 by targeting c-Myc in
gastric cancer cells, resulting in a PTEN-dependent reduction
of phospho-AKT. The observation that in DMPM cell lines
more susceptible to the cytotoxic effects of miR-34a (STO,
MP4, MP8), a decrease in phospho-AKT abundance is ob-
served early after miRNA reconstitution would suggest the
possibility that the above-describedmechanism is also operat-
ing in our models. However, results of phenocopy experi-
ments showing that siRNA-mediated silencing of c-METand
AXL was able to decrease AKT activation in sensitive cells
(STO) but not in those less susceptible to miR-34a (MesoII)
would suggest that the main mechanism controlling AKT
phosphorylation status relies on RTK activity.
Fig. 5 Silencing AXL and c-MET phenocopies miR-34a effects. STO and
MesoII cells were treated with transfection reagent (Ctrl), siNeg (siRNA
with a nonsense/scrambled sequence) or AXL- and c-MET-directed
siRNA (siAXL, siMET) for 24 hours. a Effect of AXL and/or c-MET
knockdown on cell growth, as detected by cell counting at different
times after transfection. The antiproliferative effect induced by miR-34a
reconstitution is reported for comparative purposes. b Induction of
apoptosis at 96 h after transfection, as assessed by TUNEL assay
(**p< 0.01 by Student’s t test). Data are expressed as percentage (mean
± SD) of the proliferation of siAXL-/siMET- versus siNeg-transfected cells.
c Effect of RTK-siRNA on DMPM cell matrix degrading/invasive activities.
Cells were silenced and, after 72 h, subjected to Matrigel invasion assay
in serum-free medium. The number of invading cells per field is reported.
Histogram bars represent mean values ± SD of at least three independent
experiments (***p< 0.001 by Student’s t test)
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activity in the three cell lines (STO, MesoII and MP8) able
to generate tumors following xenotransplantation into
immunodeficient mice. Although to a different extent,
miR-34a reconstitution significantly reduced the growth
of the three s.c. xenograft models. Highly relevant to the
disease, miRNA ectopic expression also impaired the
growth of STO and MP8 orthotopic xenografts, which
properly recapitulate the dissemination pattern in the
peritoneal cavity of human DMPM [11, 12], thus repre-
senting improved models to investigate novel therapeutic
approaches. Specifically, miR-34a significantly inhibited
the take of STO cells, with only one mouse developing
small tumor nodules in the abdominal cavity. Although
the miRNA did not influence the take of MP8 cells, a sig-
nificantly reduced tumor growth was observed.
Unfortunately, the inability of MP115—the only biphasic
DMPM model in our panel—to grow in vivo prevented us
to assess whether the in vitro cytostatic effect consequent
to miR-34a reconstitution, which was paralleled by the in-
duction of a senescence-like phenotype possibly sustained
by ATK activation, may result or not in tumor growth im-
pairment. However, the significantly reduced invasive po-
tential induced by miR-34a in DMPM cell lines through
the inhibition of FAK signaling could primarily contribute
to the antitumor effect observed in the xenograft models.
Moreover, the occurrence of miR-34a-induced inhibition
of cell invasion in the absence of appreciable antiprolifera-
tive and proapoptotic effects that we observed in MP115
is not surprising since the same phenotype has been previ-
ously reported by Li et al. [44] for miR-34a reconstituted
HepG2 hepatocellular carcinoma cells.
Interestingly, our evidence indicating that miR-34a
ectopic expression impairs the secretion of angiogenesis-
related factors by MesoII cells strongly suggests that the
antitumor effect observed in both s.c. and ortothopic xeno-
graft models can also rely on miRNA-induced modification
of tumor microenvironment, making it less favorable to
tumor growth.
In summary, the impressive inhibitory effects induced
by miR-34a on DMPM cell proliferation, invasion, and
growth in immunodeficient mice suggest a possible utility
of the clinically available miR-34a as novel therapeutic op-
tion for DMPM patients who are not eligible for or relapse
after CRS+HIPEC. In addition, the evidence that miR-34a
reconstitution positively modulates the activity of antitu-
mor drugs in experimental models of different human
tumor types [8, 45–47] highlights the possibility that the
miR-34a mimic could have an important role also in com-
bined strategies for treating DMPM patients.
Conclusions
DMPM is a rapidly fatal tumor with scanty therapeutic
options. Here, we demonstrated for the first time that
Fig. 6 miR-34a inhibits the invasion of DMPM cells. Cells were transfected with Ctrl, Neg, or miR-34a for 24 h. a Cells were subjected to Matrigel
invasion assay in serum-free medium 72 h after transfection. Top: the number of invading cells per field is reported. Histogram bars represent
mean values ± SD of three independent experiments (**p < 0.01; ***p < 0.001 by Student’s t test). Bottom: micrographs from one experiment
representative of three. Original magnification, × 40. b Whole-cell lysates were analyzed by western blot with anti-phospho-FAK. Protein extraction
was performed 96 h after transfection with Ctrl, Neg, or miR-34a. Vinculin was used to confirm equal protein loading. A representative experiment
of three was reported. Cropped blots are shown
Fig. 7 Effect of miR-34a restoration on the secretion of angiogenesis-related factors. a Secreted angiogenesis-related molecules were examined
by antibody arrays in conditioned medium obtained from Neg- or miR-34a-transfected MesoII cells grown for 72 h in the absence of serum. C+,
internal standards. The same conditioned media were used to assess the expression of b uPa precursor by western blot and c maspin protein by
ELISA. Each bar represents mean ± SD of triplicate samples from a representative experiment (**p < 0.01 by Student’s t test)
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Fig. 8 miR-34a inhibits DMPM tumorigenicity. a STO, MesoII, and MP8 cells were transfected with miR-34a or Neg and, on day 0, implanted
subcutaneously into the right flank of SCID mice. Micrographs show the mean tumor volumes ± SD measured at different time points after DMPM
cell injection. (*p < 0.05, **p < 0.01 by two-tailed Student’s t test). b Cropped western blot for c-MET and AXL expression in frozen tumors derived
from two additional mice sacrificed at different times (STO, 10 days; MesoII, 19 days; MP8, 25 days) after cell inoculum. Actin was used to confirm
equal protein loading
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ease induced a significant antitumor effect, which mainly
relied on c-MET and AXL down-regulation and impair-
ment of their downstream signaling. In vivo results were
complemented by in vitro data showing significant anti-
proliferative, proapoptotic, and anti-invasive activities.
Taken together, our results provide evidence that (i) c-
MET and AXL signaling pathways are critical determi-
nants of DMPM cell survival, growth, and invasiveness
and that miR-34a reconstitution can impair all these func-
tions and (ii) persistent activation of AKT and ERK1/2
downstream signaling pathways represents a cytoprotec-
tive mechanism against miRNA-induced proapoptotic ef-
fects, though not preventing its anti-invasive activity,
which instead mainly relies on FAK inhibition.
Overall, our preclinical data form a solid foundation
that could promote the clinical translation of clinically
available miR-34 mimic for the treatment of a still incur-
able disease such as DMPM and, on the other hand,
provide the first evidence of a possible cytoprotective/re-
sistance mechanism that may arise towards miRNA-
based therapeutics.Additional files
Additional file 1: Figure S1. Expression of miR-34a upon restoration in
DMPM cells. Cells were transfected with either Neg or miR-34a for 24 h. (A)
qRT-PCR analysis in the panel of DMPM cell lines 24 h after transfection. (B)
miR-34a expression by qRT-PCR in MesoII at different times after transfection.
Data are reported as −ΔΔCt between miR-34a- and Neg-transfected cells. A rep-
resentative experiment of three was reported. (TIF 236 kb)
Additional file 2: Figure S2. Effects of silencing AXL and c-MET on RTK
and downstream signaling pathways. DMPM cells were lysed 72 h after trans-
fection with RNAimax (Ctrl), control siRNA (siNeg), or AXL- and c-MET-directed
siRNAs (siAXL, siMET) for 24 h. RTK levels and activation status of ERK 1/2 or
AKT were assessed by western blot analysis. Cropped images of the protein
expression are reported. Vinculin was used to confirm equal protein loading.
(TIF 559 kb)
Additional file 3: Figure S3. a and b Effect of EGFR modulation by
miR-34a or siEGFR on DMPM cells. (a) EGFR protein expression was
assessed by western blot analysis at 72 and 96 h after 24 h transfection
with transfection reagent (Ctrl), Neg or miR-34a. Actin was used to confirm
equal protein loading. Cropped blots are presented. (b) EGFR protein
expression was determined by western blot analysis 72 h after 24 h
transfection with siNeg or EGFR-directed siRNA (siEGFR). Vinculin was used
to confirm equal protein loading. (c) DMPM cell proliferation was assessed
by cell counting at different time points after 24 h transfection with siNeg
or siEGFR. (d) DMPM cell invasion was determined in a Matrigel-based assay
at 72 h after 24 h transfection with transfection reagent (Ctrl), siNeg, or
siEGFR. (TIF 606 kb)
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